NCT06549946View on ClinicalTrials.gov

Ixovex-1 Single Agent and Combination Therapy

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

December 17, 2024

Primary Completion Date

January 30, 2027

Study Completion Date

January 30, 2027

Conditions

Solid TumorHead and Neck Cancer

Interventions

BIOLOGICAL

Ixovex-1

Ixovex-1 is a novel oncolytic human adenovirus serotype 5.

BIOLOGICAL

Pembrolizumab

Humanised antibody

Trial Locations (1)

SW3 6JJ

RECRUITING

The Royal Marsden, London

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

IQVIA Biotech

INDUSTRY

lead

Psivac Ltd

INDUSTRY